
|Videos|July 5, 2021
Assessing the Use of Dapagliflozin in Patients With Type 2 Diabetes Hospitalized With COVID-19
Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, discussed how the phase 3 DARE-19 trial was conducted to assess dapagliflozin in patients with type 2 diabetes hospitalized with COVID-19.
Advertisement
Pharmacy Times interviewed Mikhail Kosiborod, MD, cardiologist and vice president of research at Saint Luke's Health in Kansas City, on the results from the DARE-19 trial assessing the efficacy and safety of dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.
During the discussion, Kosiborod explained how the phase 3 DARE-19 trial was conducted to assess dapagliflozin in patients with and without type 2 diabetes hospitalized with COVID-19.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months
2
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
3
Navigating REMS: Challenges, Perspectives, and the Path Forward for Bispecific Antibody Programs
4
Building a Pharmacist-Led Furoscix Workflow From Scratch
5


































































































